Cardiovascular toxicity of antitumor therapy for breast cancer in women: risk stratification and outcome prediction

Authors

Keywords:

breast cancer, cardio-oncology, cardiovascular toxicity, antitumor therapy

Abstract

Risk stratification and prediction of cardiovascular toxicity development during antitumor therapy for breast cancer is a pressing issue in modern healthcare. According to a number of studies, the risk of cardiovascular mortality is 1.8 times higher among women who received antitumor therapy for breast cancer, which is due to the cardiovascular toxicity of the drugs used and the prevalence of cardiovascular diseases.

Objective: analysis of literature on risk stratification and prediction of cardiovascular toxicity outcomes during antitumor therapy for breast cancer in women.

Author Biographies

  • Alexandra A. Dey, Far Eastern Federal University

    Сandidate of Medical Sciences, Associate Professor, School of Medicine and Life Sciences

  • Boris I. Geltser, Far Eastern Federal University

    Corresponding Member of the Russian Academy of Sciences, Professor, Professor, Associate Professor, School of Medicine and Life Sciences

  • Ksenia E. Makarova, Far Eastern Federal University

    Candidate of Biological Sciences, Associate Professor, School of Medicine and Life Sciences

  • Kirill V. Stegniy, Far Eastern Federal University

    Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Professor, School of Medicine and Life Sciences

  • Yulia Y. Petukhova , Primorsky Regional Oncology Dispensary

    Сandidate of Medical Sciences, Deputy Chief Physician for Medical Work

  • Oleg A. Argishev , Primorsky Regional Oncology Dispensary

    Head of the Oncology Department of Surgical Methods for Treating Breast Tumors

References

1. Бродская Т.А., Гельцер Б.И., Саталкина Т.С., Кныш С.В., Шекунова О.И. Артериальная гипертензия и рак молочной железы у женщин: механизмы коморбидности и лекарственной ятрогении // Артериальная гипертензия. 2022. Т. 28, № 2. С. 147–156. DOI: https://doi.org/10.18705/1607-419X-2022-28-2-147-156

2. Patnaik J.L., Byers T., DiGuiseppi C., Dabelea D., Denberg T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Research, 2011, vol. 13, art. R64. DOI: https://doi.org/10.1186/bcr2901

3. Бродская Т.А., Саталкина Т.С., Гельцер Б.И., Котельников В.Н. Оценка факторов кардиометаболического риска у женщин с раком молочной железы до и после химиотерапии доксорубицином и циклофосфамидом // Российский кардиологический журнал. 2025. Т. 30, № 1. С. 58–66. DOI: https://doi.org/10.15829/1560-4071-2025-5951

4. Park N.J., Chang Y., Bender C., et al. Cardiovascular disease and mortality after breast cancer in postmenopausal women: results from the Women's Health Initiative. PLoS ONE, 2017, vol. 12, no. 9, art. e0184174. DOI: https://doi.org/10.1371/journal.pone.0184174

5. Zhang S., Liu X., Bawa-Khalfe T., Lu L.-S., Lyu Y.L., Liu L.F., Yeh E.T.H. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine, 2012, vol. 18, no. 11, pp. 1639–1642. DOI: https://doi.org/10.1038/nm.2919

6. Narayan H.K., Finkelman B., French B., et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over three years of follow-up. Circulation, 2017, vol. 135, no. 15, pp. 1397–1412. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.023463

7. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. European Heart Journal, 2013, vol. 34, no. 15, pp. 1102–1111. DOI: https://doi.org/10.1093/eurheartj/ehs181

8. Lyon A.R., Lopez-Fernandez T., Couch L.S., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiation and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 2022, vol. 43, no. 41, pp. 4229–4361. DOI: https://doi.org/10.1093/eurheartj/ehac244

9. Черняк С.В., Ковш Е.В., Севрук Т.В., Ахмед Н.Н., Павлова О.С. Профилактика ранней кардиотоксичности при системном лечении резектабельного рака молочной железы // Кардиология в Беларуси. 2023. Т. 15, № 2. С. 193–203. DOI: https://doi.org/10.34883/PI.2023.15.2.003

10. Rubinstein R., Kuvin J.T., Soffler M., et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. European Heart Journal, 2010, vol. 31, pp. 1142–1148.

11. Dong J., Chen H. Cardiotoxicity of anticancer therapeutics. Frontiers in Cardiovascular Medicine, 2018, vol. 9, no. 5, art. 9. DOI: https://doi.org/10.3389/fcvm.2018.00009

12. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 2015, vol. 12, no. 9, pp. 547–558. DOI: https://doi.org/10.1038/nrcardio.2015.65

13. Hahn V.S., Lenihan D.J., Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. Journal of American Heart Association, 2014, vol. 3, no. 2, art. e000665. DOI: https://doi.org/10.1161/JAHA.113.000665

14. Proctor M., Suter T.M., de Azambuja E., et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. Journal of Clinical Oncology, 2010, vol. 28, pp. 3422–3428. DOI: https://doi.org/10.1200/JCO.2009.26.0463

15. Плохова Е.В., Дундуа Д.П. Кардиоонкология. Основные принципы профилактики и лечения кардиотоксичности на фоне химиотерапии у онкологических пациентов // Клиническая практика. 2019. Т. 10, № 1. С. 30–40. DOI: https://doi.org/10.17816/clinpract10130–40

16. Кузьмина Т.П., Давыдкин И.Л., Терешина О.В. и др. Кардиотоксичность и методы её диагностики у пациентов гематологического профиля (Обзор литературы) // Сибирский научный медицинский журнал. 2019. Т. 39, № 1. С. 34–42. DOI: https://doi.org/10.15372/SSMJ20190105

17. Гумерова К.С., Сахаутдинова Г.М., Полякова И.М. Кардиоваскулярная токсичность, индуцированная применением противоопухолевых препаратов, и современные методы лечения опухолевых новообразований // Креативная хирургия и онкология. 2019. № 9(4). С. 285–292. DOI: https://doi.org/10.24060/2076-3093-2019-9-4-285-292

18. Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии // Российский кардиологический журнал. 2021. Т. 26, № 9. С. 4703. DOI: https://doi.org/10.15829/1560-4071-2021-4703

19. Internet portal of the Russian Society of Oncologists. URL: https://www.rosoncoweb.ru/standarts/RUSSCO/ (accessed: 01.05.2025).

20. Бродская Т.А., Саталкина Т.С., Гельцер Б.И. и др. Оценка факторов кардиометаболического риска у женщин с раком молочной железы до и после химиотерапии доксорубицином и циклофосфамидом // Российский кардиологический журнал. 2025. Т. 30, № 1. С. 58–66. DOI: https://doi.org/10.15829/1560-4071-2025-5951

21. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Progress in Cardiovascular Disease, 2007, vol. 49, pp. 330–352.

22. Kong C.Y., Guo Z., Song P., et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. International Journal of Biological Sciences, 2022, vol. 18, no. 2, pp. 760–770. DOI: https://doi.org/10.7150/ijbs.65258

23. Лимарева С.В. Таксаны в адъювантной и неоадъювантной терапии рака молочной железы // Опухоли женской репродуктивной системы. 2010. № 4. С. 15–23. DOI: https://doi.org/10.17650/1994-4098-2010-0-4-15-23

24. Zamorano J.L., Lancellotti P., Rodriguez Munoz D., et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). European Heart Journal, 2016, vol. 37, no. 36, pp. 2768–2801. DOI: https://doi.org/10.1093/eurheartj/ehw211

25. Mourad J.J., Des Guetz G., Debbabi H., et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Annals of Oncology, 2008, vol. 19, pp. 927–934.

26. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc., 2014, vol. 89, no. 9, pp. 1287–1306. DOI: https://doi.org/10.1016/j.mayocp.2014.05.013

27. Потиевская В.И., Ахобеков А.А., Болотина Л.В. и др. Кардиоваскулярные осложнения противоопухолевой терапии рака молочной железы: диагностика, профилактика и лечение // Сибирский онкологический журнал. 2021. Т. 20, № 5. С. 138–148. DOI: https://doi.org/10.21294/1814-4861-2021-20-5-138-148

28. Чичканова А.С., Тарловская Е.И., Субботин A.K. Оценка кардиотоксичности химиотерапевтического лечения у пациентов с раком молочной железы по данным локального регистра // Вопросы онкологии. 2022. Т. 68, № S3. С. 480–481. EDN: ILXLUP

Downloads

Published

2025-06-11

Issue

Vol. 1 No. 2 (2025)

Section

ONCOLOGY, RADIATION THERAPY

License

Copyright (c) 2025 Александра Анатольевна Дей, Борис Израйльевич Гельцер, Ксения Евгеньевна Макарова, Кирилл Владимирович Стегний , Юлия Юрьевна Петухова , Олег Александрович Аргишев

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Cardiovascular toxicity of antitumor therapy for breast cancer in women: risk stratification and outcome prediction. (2025). Clinical and Fundamental Medicine, 1(2), 34-43. https://journals.dvfu.ru/clinfundmed/article/view/1747

Most read articles by the same author(s)